Le Baut Guillaume, Guilloit Jean-Marc, Leprince Vincent, Ollivier Yann, Dubos-Arvis Catherine, Do Pascal, Sutter Jasmine, Loge Ludovic, Gervais Radj
Department of Gastroenterology and Hepatology, Teaching Hospital of Caen, Caen, France.
Department of Medical Oncology, Regional Cancer Centre of Caen, Caen, France.
J Gastrointest Oncol. 2018 Jun;9(3):E15-E18. doi: 10.21037/jgo.2018.01.01.
Oxaliplatin given systemically is associated with pneumonitis in less than 1% of cases. This case report describes acute respiratory failure, due to bronchiolitis organising pneumonia, in a patient with colorectal carcinoma being treated with hyperthermic intraperitoneal chemotherapy which included oxaliplatin and CPT-11 (irinotecan). The clinical course, the lack of an identifiable infectious agent and the complete response to corticosteroids suggested a drug-induced cause. After ruling out CPT-11, oxaliplatin was considered to be the causal agent. The unusual feature of this case was that pneumonitis developed after intraperitoneal administration of oxaliplatin. Oxaliplatin-associated respiratory complications can occur whatever route the drug is administered.
全身给予奥沙利铂时，肺炎的发生率不到1%。本病例报告描述了一名接受含奥沙利铂和CPT-11（伊立替康）的腹腔内热化疗的结直肠癌患者，因机化性肺炎型细支气管炎导致急性呼吸衰竭。临床病程、未发现可识别的感染病原体以及对皮质类固醇的完全反应提示为药物性病因。排除CPT-11后，奥沙利铂被认为是致病因素。该病例的不寻常之处在于，肺炎在腹腔内给予奥沙利铂后发生。无论通过何种途径给药，奥沙利铂相关的呼吸系统并发症都可能发生。
